These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9198065)

  • 1. Decrease in the haemoglobin level in haemodialysis patients undergoing antiandrogen therapy.
    Teruel JL; Cano T; Marcén R; Villafruela JJ; Rivera M; Fernández-Juarez G; Ortuño J
    Nephrol Dial Transplant; 1997 Jun; 12(6):1262-3. PubMed ID: 9198065
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
    Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
    Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer.
    Crawford ED
    Urology; 1995 Dec; 46(6):899-901. PubMed ID: 7502440
    [No Abstract]   [Full Text] [Related]  

  • 4. Intermittent androgen suppression--ready for prime time?
    Ischia J; Goldenberg SL
    J Urol; 2012 Jun; 187(6):1956-7. PubMed ID: 22503023
    [No Abstract]   [Full Text] [Related]  

  • 5. Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer.
    Lin CJ; Hsieh RK; Lim KH; Chen HH; Cheng YC; Wu CJ
    South Med J; 2007 Sep; 100(9):916-7. PubMed ID: 17902299
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant hormonotherapy in patients with clinically-localized prostate cancer treated by radical prostatectomy: pathological results.
    Têtu B
    Can J Oncol; 1994 Nov; 4 Suppl 1():33-4; discussion 35-6. PubMed ID: 8853487
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Watchful waiting beats androgen deprivation therapy in early prostate cancer.
    Brower V
    J Natl Cancer Inst; 2008 Nov; 100(21):1494-6. PubMed ID: 18957680
    [No Abstract]   [Full Text] [Related]  

  • 9. [Combination effect of flutamide and leuprorelin acetate on growth of Dunning R3327-H prostatic adenocarcinoma in rats].
    Tomura A; Kuroiwa S; Okada M; Abe F
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):563-9. PubMed ID: 9530363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Histological investigation of prostate cancer treated with hormonal agents].
    Azumi M; Saga Y; Hashimoto H; Kakizaki H
    Hinyokika Kiyo; 2006 Oct; 52(10):781-4. PubMed ID: 17131867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
    Figg WD; Dawson N; Middleman MN; Brawley O; Lush RM; Senderowicz A; Steinberg SH; Tompkins A; Reed E; Sartor O
    Acta Oncol; 1996; 35(6):763-5. PubMed ID: 8938230
    [No Abstract]   [Full Text] [Related]  

  • 12. Response of carcinoma of the prostate to withdrawal of flutamide.
    Collinson MP; Daniel F; Tyrrell CJ; Teasdale C
    Br J Urol; 1993 Nov; 72(5 Pt 1):662-3. PubMed ID: 10071562
    [No Abstract]   [Full Text] [Related]  

  • 13. [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT].
    Sumiyoshi Y; Hashine K; Kuwahara M; Aki M; Yamamoto A; Akazawa S; Takenaka A
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1153-8. PubMed ID: 10431581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute renal failure in a patient receiving treatment with suramin.
    Smith A; Harbour D; Liebmann J
    Am J Clin Oncol; 1997 Aug; 20(4):433-4. PubMed ID: 9256906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiandrogen withdrawal syndrome in relapsed prostate cancer.
    Scher HI; Kolvenbag GJ
    Eur Urol; 1997; 31 Suppl 2():3-7; discussion 24-7. PubMed ID: 9074903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
    Ng E; Woo HH; Turner S; Leong E; Jackson M; Spry N
    J Urol; 2012 Jun; 187(6):2162-6. PubMed ID: 22503022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in body composition during androgen deprivation therapy for prostate cancer.
    Smith MR; Finkelstein JS; McGovern FJ; Zietman AL; Fallon MA; Schoenfeld DA; Kantoff PW
    J Clin Endocrinol Metab; 2002 Feb; 87(2):599-603. PubMed ID: 11836291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Diamond T; Campbell J; Bryant C; Lynch W
    Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial.
    Mottet N; Van Damme J; Loulidi S; Russel C; Leitenberger A; Wolff JM;
    BJU Int; 2012 Nov; 110(9):1262-9. PubMed ID: 22502816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Total androgen blockade--concept, theory, method and clinical application].
    Ozono S; Hirao Y
    Nihon Rinsho; 1998 Aug; 56(8):2129-34. PubMed ID: 9750521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.